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Abstract: 
Background: There is limited data on results of central re-testing of samples from patients with 
invasive breast cancer categorised in their local hospital laboratories as oestrogen receptor (ER) 
positive and human epidermal growth factor receptor homologue 2 (HER2) negative. 
Methods: The Optimal Personalised Treatment of early breast cancer usIng Multiparameter 
Analysis preliminary study (OPTIMA prelim) was the feasibility phase of a randomised controlled 
trial to validate the use of multiparameter assay directed chemotherapy decisions in the UK 
National Health Service (NHS). Eligibility criteria included ER positivity and HER2 negativity. 
Central re-testing of receptor status was mandatory. 
Results: Of the 431 patients tested centrally, discrepant results between central and local 
laboratory results were identified in only 19 (4.4%; 95% confidence interval 2.5%-6.3%) patients 
(with 21 tumours). On central review, seven patients had cancers that were ER negative (1.6%) 
and/or HER2 positive (13 (3.2%) patients with 15 tumours); including one tumour discrepant for 
both biomarkers. 
Conclusion: Central re-testing of receptor status of invasive breast cancers in the UK NHS setting 
shows a high level of reproducibility in categorising tumours as ER positive and HER2 negative and 
raises questions regarding the costs and the value of central re-testing in this sub-group of breast 
cancers in this setting. 
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Introduction 
 
Oestrogen receptor (ER) and human epidermal growth factor receptor homologue 2 (HER2) are 
established biomarkers in invasive breast cancer and form the backbone of clinical decision 
making related to targeted therapies in the adjuvant setting. Although data from external quality 
assurance schemes (such as UK NEQAS ICC), successful participation in which is mandatory for UK 
laboratories, indicates good performance for testing these receptors nationally, there is relatively 
little published evidence comparing local results to central re-testing of local ER and HER2 
expression in large clinical trial datasets. In particular, information from central laboratory 
testing/validation of series of invasive breast carcinomas that have been designated as ER positive 
and HER2 negative is limited; reports have largely described data from central re-testing of breast 
cancers which have been recorded as HER2 positive in local laboratories, such as in the Breast 
Intergroup Trial N9831 [Roche 2002][Suman 2006]. However, some of these publications have 
indicated alarming proportions of discrepancy in defining HER2 positivity. There are fewer 
publications comparing central repeat testing of hormone receptors from clinical trial samples but 
Viale et al examined 6291 of 8010 tumours from women in BIG1-98 and found that 
central review confirmed 97% of tumours were hormone receptor-positive (defined as ER and/or 
PgR > or = 10%) [Viale 2007]. Using tissue microarrays (TMAS) of tumours in the Tamoxifen and 
Exemestane Adjuvant Multinational (TEAM) trial, of 4325 cases with sufficient material only 42 
were ER negative (0.99%), of these 28 were PgR positive and only 14 ER negative/PgR negative 
tumours were identified (0.3%) [Bartlett 2011]. 
 
The accuracy of defining hormone receptor positive and HER2 negative invasive breast cancer in 
local centres is clearly vital for patient management outside of the clinical trial setting, but also 
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has significant resource and cost implications within randomised trials where ER and/or HER2 are 
critical components of eligibility. The question remains whether local biomarker results are 
sufficiently robust to allow trialists to avoid the costly re-analysis of biomarkers in central 
laboratories to confirm patient eligibility. To address this question we have examined data in the 
UK setting within OPTIMA prelim.  
 
Material and methods: 
 
The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis 
preliminary study (OPTIMA prelim) (ISRCTN42400492) was the feasibility phase of a randomised 
controlled trial designed to validate the use of multiparameter assay directed chemotherapy 
decisions in the UK National Health Service [Bartlett 2013][Stein 2016][Bartlett JM et al. 2016]. 
Patients were aged ≥ 40 years at entry with surgically treated ER positive, HER2 negative primary 
invasive breast cancer, with 1 to 9 involved axillary nodes or, if node negative, a tumour of at least 
30mm in maximum dimension. Patients were randomised to standard care (chemotherapy 
followed by endocrine therapy) or an Oncotype DX® test (Genomic Health Inc., Redwood City, CA, 
USA) was performed on the surgically resected tumour to assign patients either to standard care 
(if 'recurrence score' (RS) was > 25), or to endocrine therapy alone (if RS was ≤ 25). In this 
feasibility study, ER and HER2 were both reassessed by a central laboratory (UCL Advanced 
Diagnostics) after registration into the trial to confirm eligibility prior to randomisation.  
 
ER was assessed centrally on whole tissue sections by immunohistochemistry (6F11; Leica 
Biosystems) and an Allred score of 3 or more was regarded as positive, as per national guidance 
at that time [Harvey JM et al. 1999]. If central ER results were discordant with the local report, 
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and there was any doubt, the assay was repeated with a second antibody (EP1, Dako). HER2 was 
re-assessed centrally with dual-color dual-hapten brightfield in situ hybridisation (DDISH) 
(Ventana Medical Systems) and, as per UK national guidelines, a ratio of Her2 to chromosome 17 
centromeric probe (CEP17) of 2.00 - 2.20 was considered to represent borderline/positive gene 
amplification, whilst a ratio of Her2:CEP17 of >2.20 was regarded as Her2 gene amplification 
[Bartlett et al, 2011]. If DDISH proved unsuccessful, FISH was attempted using the HER2 
PathVysion probe (HER2 PathVysion; Abbott Molecular). Her-2 Immunohistochemistry (4B5; 
Ventana Medical Systems) was applied in cases where no result was achievable by either HER2 
ISH technique.  
 
Results 
 
Between October 2012 and August 2014, 442 patients were registered into OPTIMA prelim, but 
11 patients were subsequently withdrawn prior to central testing. Thus a total of 431 patients had 
their tumours tested centrally. Nineteen patients with 21 tumours, showed discrepancies in 
receptor status between local and central laboratory results (4.4%; 95% confidence interval (CI) 
2.5%-6.3%). The remaining 412 patients (95.6%) with concordant results went on to be 
randomised into OPTIMA prelim. 
 
Seven tumours in 7 patients (1.6%) were found to be ER negative on central re-testing (Table 1). 
Two of the 7 were heterogeneous, with an uncommon admixture of ER negative and ER positive 
cells identified in the surgically excised tumour. Two appear to represent true errors in local 
laboratory tests; as local laboratory re-testing on the same sample found the tumours to indeed 
be ER negative (personal communications). In one case, an interpretive difference remained 
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between the local and central testing; the core and the excision specimen were both reassessed 
locally as showing low level ER expression (Allred score 3 in the core biopsy) by the local 
pathologist. Unfortunately, despite liaison with the laboratories it has not been possible to 
discover whether ER status has been re-assessed locally for other two discrepant tumours.  
 
In total 15 tumours in 13 patients (3.0%) from the total 431 patients tested centrally were 
discrepant for HER2 results (Table 2). One patient had one tumour that was centrally categorised 
as ER negative and also showed Her2 amplification (ratio of Her2:CEP17 = 3.59). Seven others also 
showed Her2 amplification (ratio of Her2:CEP17 ranged from 2.39-3.92). An additional patient had 
one tumour that was Her2 amplified and one tumour that was borderline amplified (ratio of 
Her2:CEP17 = 2.78 and 2.11, respectively). The remaining four patients had tumours showing 
borderline Her2 gene amplification (ratio between 2.00-2.20); including one patient with two 
tumours both showing borderline amplification. Only three of the 15 tumours demonstrated what 
some consider ‘high-level’ gene amplification (ratio >3.00) [Starczynski 2012] and none what 
others have described as ‘high-grade’ amplification (ratio >/=4.00) [Seol 2012]. 
 
It has not been possible to ascertain if there has been repeat HER2 testing (immunohistochemistry, 
or FISH or DDISH) on all of these 13 cases; for 5 women (with 7 tumours) the local team have 
managed the patient as per the central, HER2 positive, results without apparent retesting. In 3 
further cases data has not been obtainable. In 4 cases local retesting has been undertaken: in 2 
cases (one by FISH, other method uncertain) the local laboratory results have remained HER2 
negative (both tumours borderline amplified by Her2:CEP17 ratio centrally), i.e. results remaining 
discrepant; one case was agreed to be HER2 
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 positive by re-testing locally by FISH; the final case on local repeat testing had a Her2:CEP17 ratio 
of >2.00 but the local pathologist maintained that the tumour should be regarded as HER2 
negative because of low average Her2 copy number. One case was negative 
immunohistochemically but showed Her2 gene amplification (3.92). 
 
 
Discussion 
 
Central re-testing of HER2 positive breast cancers has shown high levels of variability in some 
clinical trials; for example, HER2 positivity was only confirmed in 85.8% of 2,535 patients in the 
North Central Cancer Treatment Group N9831 intergroup adjuvant trial [Perez EA et al 2006]. 
Some of these trials, however, pre-date stringent guidelines for HER2 assessment and reporting 
and the reasons for discordance is often not clear. The value of central re-testing of breast cancers 
defined locally as HER2 negative as an eligibility criterion for other, more recent, clinical trials has 
not been well studied. Outwith clinical trials generally lower degrees of discrepancy, have been 
reported [Vani K 2008][Kaufman 2014]; for example, Kaufman et al identified that only 4% of 552 
patients with metastatic HER2 negative carcinoma (defined locally) in a large observational cohort 
were HER2 positive on central re-testing [Kaufman 2014]. These data are essentially similar to the 
results in our UK clinical trial where 4.4% of tumours defined locally as HER2 negative were HER2 
positive on central re-analysis. 
 
These data highlight that approximately 3% of patients could be being excluded from HER2 
directed therapies due to a potentially faulty local result in real-world testing in the UK. However, 
of note, we report here the proportion of cases that are discordant between local and central 
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laboratory testing. Although for 2 cases, repeat re-testing of the same samples locally confirmed 
the tumour was ER negative (rather than ER positivity as initially reported), for others it is only 
possible to record that the other results were “discordant”. It is not per se the case that the central 
laboratory is correct and the local laboratory inaccurate, since both adhere to the same quality 
assurance and reporting guidelines.  
 
Central repeat testing of hormone receptor status from clinical trial samples have reported similar, 
albeit slightly higher, levels of difference between local and central laboratories than we have 
found. Viale et al. [Viale 2007] examined 6291 of 8010 tumours from women in BIG1-98 and found 
that central review confirmed 97% of tumours were hormone receptor-positive, although this 
incorporated both ER and progesterone receptor and with different cut-offs than applied as 
routine in the UK (i.e. defined as ER and/or PgR > or =10%). Indeed, the authors note that, of 105 
carcinomas that were reported locally as ER negative, 73 had >10%, and eight had 1% - 9% positive 
cells. This highlights the difficulty of non-standard definitions globally for hormone receptor 
positivity and the need for pathologists, as well as all other members of the multidisciplinary team, 
to be aware of study protocols and definitions.  
 
Notwithstanding that these results compare favourably to the (albeit limited) published data, 
there are a number of possible explanations for discrepant results between local and central 
laboratories. Additional challenges include variation in methodology (for example, 
immunohistochemistry Vs fluorescence in situ hybridisation (FISH) Vs chromogenic in situ 
hybridisation (DDISH) for assessment of HER2 status), as well as differences in the antibody clones 
used, variation in the material assessed (cores Vs surgical excision specimens) and pathologist 
interpretation. It is well recognised that variation between core biopsy specimens and surgical 
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excision is uncommon (<2% of cases showing heterogeneity) [Arnedos 2009][Lee 2012], although 
this clearly does occur and may potentially explain variations in receptor status if different 
specimens are submitted for central testing than examined locally. Indeed, this variation appears 
to explain at least 2 of the 7 cases with discrepant ER status in this study. 
 
These potential discrepancies are all applicable even if the central review is undertaken in ‘real 
time’, i.e. prior to patient randomisation as in OPTIMA prelim. Nevertheless, particular care must 
be taken when analysing historical data on ER status, even in meta-analysis of clinical trials or 
when comparing to present day results; data extracted from local reports may be based on 
entirely different methodologies; Collins et al examined (on TMA) 1851 cases where tissue and 
histology reports were available and highlighted that in 82% of the cases the original assays were 
biochemical. Even where immunohistochemistry was applied both locally and centrally as the 
technique of choice, agreement was only 92% for ER status (310 of 336 specimens) [Collins 2008]. 
Again, the 1.6% difference seen in OPTIMA prelim compares favourably. 
 
Despite all the potential technical and interpretive differences in biomarker analysis, the results 
from OPTIMA prelim indicate good concordance between local laboratories and central re-testing 
centre in the UK in classification of invasive breast cancers as ER positive and HER2 negative. Such 
re-testing in large randomised clinical trials recruiting thousands of patients is very expensive and, 
in the setting of this group of patients (as opposed to HER2 positive disease, for example, where 
discrepancies may be higher), the value is questionable.  
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Table 1: Details of the 7 patients (from 431 patients registered and tested centrally) with 
discrepant oestrogen receptor results. 
  
Patient 
CENTRAL ER RESULTS   
ER Status 
Allred 
score 
% tumour 
cell 
positivity 
Comment 
A Negative 0 0 Two clonality distinct tumours - part 
positive and part negative for ER. Original 
ER on core biopsy. 
B Negative 0 0 ER repeated in local laboratory on core 
biopsy using different antibody/clone and 
negative staining for ER confirmed. 
C Negative 0 0 ER retested locally and confirmed to be 
negative. 
D Negative 0 0   
E Negative 0 0 Heterogenous tumour, at least focally ER 
negative. 
F Negative 0 0   
G Negative 0 0 3 tumours: 2 eligible, 1 ineligible 
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Patient 
CENTRAL HER2 RESULTS 
HER2 STATUS 
Her2: 
CEP17 
ratio 
Average 
CEP17 copy 
number per 
cell 
Average Her2 
copy number 
per cell 
Comments 
D Amplified 3.59 1.10 3.95 Also ER negative on 
central testing 
H Borderline amplified 2.00 2.78 5.55 
 
I1* Borderline amplified 2.14 1.65 3.53   
I2* Borderline amplified 2.06 1.69 3.47   
J Borderline amplified 2.20 1.43 3.14   
K Amplified 2.70 2.00 5.40   
L Amplified 2.39 1.55 3.70   
M Amplified 2.81 1.35 3.80 Heterogeneous - testing 
of core (locally) and 
second block (centrally) 
showed Her2 non-
amplified foci. 
N Amplified 3.23 2.80 9.05   
O1* Amplified 2.78 1.35 3.75   
O2* Borderline amplified 2.11 1.40 2.95   
P Amplified 2.45 1.10 2.70   
Q Amplified 2.64 1.08 2.83   
R Amplified 3.92 1.85 7.25   
S Borderline amplified  2.11 2.03 4.30   
 
Table 2: Details of the 15 discrepant tumours (13 patients) for human epidermal growth factor 
receptor homologue 2 (HER2) status.  
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Amplified: human epidermal growth factor receptor homologue 2 (HER2) to chromosome 17 
centromeric probe (CEP17) ratio >2.20; borderline amplified: HER2 to CEP17 ratio 2.00-2.20. *G1 
& G2, and N1 & N2, are tumours from the same patients respectively. 
